Diabetic Gastroparesis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
Global diabetic gastroparesis treatment market is poised for a significant upswing in the coming years, as highlighted by a comprehensive market analysis. With a projected Compound Annual Growth Rate (CAGR) of 5.1% from 2024 to 2031. This growth trajectory underscores a burgeoning demand for effective treatments against diabetic gastroparesis (DGP), a condition predominantly affecting individuals with Type-1 and Type-2 diabetes, particularly females with Type-2 diabetes.
Market Dynamics
The increasing prevalence of diabetes worldwide, coupled with a heightened focus on addressing the substantial unmet medical needs associated with diabetic gastroparesis, is propelling market growth. The availability of reimbursement options for in-patient hospital stays in developed countries further augments this trend. Enhanced accessibility to medications and an overall improvement in affordability are also contributing to the expansion of the market.
However, the market faces challenges such as the prevalent use of non-prescription drugs for symptom management, which may impede early diagnosis of the condition. Additionally, the lack of robust clinical evidence supporting the efficacy of prescription drugs and the premature termination of clinical trials pose significant hurdles to market growth.
Innovations and Trends
A key trend shaping the market landscape is the shift towards consumer-friendly pricing models for drugs and treatment devices, aiming to increase treatment uptake globally. Innovations in product offerings, along with creative marketing strategies employed by key market players, are expected to enhance market penetration and facilitate the entry of new treatment modalities.
Market Segmentation Insights
The global diabetic gastroparesis treatment market is segmented based on product type, disease indication, and distribution channel. Drugs as a product type dominate the market and are projected to continue leading in revenue generation, throughout the forecast period. The surgical treatment products segment is anticipated to witness a higher CAGR, attributed to the long-term relief these interventions offer.
Compensated gastroparesis dominates the disease indications market, poised for steady growth. Among distribution channels, hospital pharmacies lead the way, with e-commerce channels also witnessing increasing popularity.
Regional Outlook
North America leads the global market, with the fastest growth rate of CAGR anticipated during the forecast period, owing to advanced healthcare infrastructure and high awareness levels. The Asia Pacific region is identified as a highly attractive market, offering significant opportunities for drug manufacturers and investors, due to its high CAGR. The Middle East & Africa region, although accounting for a smaller share of the global market, is expected to witness a steady growth rate.
Key Players in the Market
Prominent companies such as Janssen Global Services, LLC, Salix Pharmaceuticals, Inc., Abbott Laboratories, Medtronic, C. R. Bard, Inc., Kimberly-Clark Corporation, Boston Scientific Corporation, Cardinal Health, Inc., Rhythm Pharmaceuticals, Inc., Evoke Pharma, and Alfa Wassermann SPA are leading the charge in developing and marketing diabetic gastroparesis treatments.
Market Segmentation
By Product Type
• Drugs
• Gastroprokinetic Agents
• Antiemetic Agents
• Botulinum Toxin
• Surgical Treatment Products
• Gastric Electrical Stimulation (GES) Devices
• Percutaneous Endoscopic Gastrostomy (PEG) Kit
• Parenteral Nutrition
By Region
• North America Market
• Latin America Market
• Europe Market Value
• APAC Market Value
• MEA Market Value
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.